Education
About Us
Working with TipRanks
Follow Us
Prostatype Genomics AB (SE:PROGEN)
:PROGEN
Total Valuation
Prostatype Genomics AB has a market cap or net worth of kr56.11M. The enterprise value is kr22.22M.
Market Capkr56.11M
Enterprise Valuekr22.22M
Share Statistics
Prostatype Genomics AB has 59,189,320 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding59,189,320
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Prostatype Genomics AB’s return on equity (ROE) is -1.68 and return on invested capital (ROIC) is -147.31%.
Return on Equity (ROE)-1.68
Return on Assets (ROA)-0.87
Return on Invested Capital (ROIC)-147.31%
Return on Capital Employed (ROCE)-1.47
Revenue Per Employee99.00K
Profits Per Employee-7.42M
Employee Count6
Asset Turnover0.01
Inventory Turnover489.87
Valuation Ratios
The current PE Ratio of Prostatype Genomics AB is ―. Prostatype Genomics AB’s PEG ratio is 0.00252.
PE Ratio―
PS Ratio17.06
PB Ratio0.38
Price to Fair Value0.38
Price to FCF-0.42
Price to Operating Cash Flow-0.41
PEG Ratio0.00252
Income Statement
In the last 12 months, Prostatype Genomics AB had revenue of 594.00K and earned -44.50M in profits. Earnings per share was -1.32.
Revenue594.00K
Gross Profit-37.62M
Operating Income-39.08M
Pretax Income-44.50M
Net Income-44.50M
EBITDA-36.89M
Earnings Per Share (EPS)-1.32
Cash Flow
In the last 12 months, operating cash flow was -38.58M and capital expenditures -514.00K, giving a free cash flow of -39.09M billion.
Operating Cash Flow-38.58M
Free Cash Flow-39.09M
Free Cash Flow per Share-0.66
Dividends & Yields
Prostatype Genomics AB pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.49
52-Week Price Change-59.49%
50-Day Moving Average1.23
200-Day Moving Average0.88
Relative Strength Index (RSI)42.10
Average Volume (3m)300.11K
Important Dates
Prostatype Genomics AB upcoming earnings date is Aug 13, 2026, TBA (Confirmed).
Last Earnings DateFeb 26, 2026
Next Earnings DateAug 13, 2026
Ex-Dividend Date―
Financial Position
Prostatype Genomics AB as a current ratio of 0.44, with Debt / Equity ratio of 0.00%
Current Ratio0.44
Quick Ratio0.43
Debt to Market Cap0.00
Net Debt to EBITDA0.25
Interest Coverage Ratio-24.20
Taxes
In the past 12 months, Prostatype Genomics AB has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Prostatype Genomics AB EV to EBITDA ratio is -0.03, with an EV/FCF ratio of -0.04.
EV to Sales1.80
EV to EBITDA-0.03
EV to Free Cash Flow-0.04
EV to Operating Cash Flow-0.04
Balance Sheet
Prostatype Genomics AB has kr12.93M in cash and marketable securities with kr0.00 in debt, giving a net cash position of kr12.93M billion.
Cash & Marketable Securitieskr12.93M
Total Debtkr0.00
Net Cashkr12.93M
Net Cash Per Sharekr0.22
Tangible Book Value Per Sharekr0.79
Margins
Gross margin is -1570.25%, with operating margin of -6579.12%, and net profit margin of -7492.09%.
Gross Margin-1570.25%
Operating Margin-6579.12%
Pretax Margin-7492.09%
Net Profit Margin-7492.09%
EBITDA Margin-6210.94%
EBIT Margin-6579.12%
Analyst Forecast
The average price target for Prostatype Genomics AB is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-67.76%
EPS Growth Forecast95.76%